We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+47.15%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$876M
AUM Growth
+$142M
Cap. Flow
-$21.2M
Cap. Flow %
-2.42%
Top 10 Hldgs %
56.33%
Holding
39
New
2
Increased
1
Reduced
4
Closed
2

Top Buys

1
AGIO icon
Agios Pharmaceuticals
AGIO
+$21.1M
2
DYN icon
Dyne Therapeutics
DYN
+$12.3M
3
ELVN icon
Enliven Therapeutics
ELVN
+$9.43M

Top Sells

1
MLYS icon
Mineralys Therapeutics
MLYS
+$39.2M
2
CMPS
Compass Pathways
CMPS
+$11M
3
SLNO
Soleno Therapeutics
SLNO
+$6.64M
4
KURA icon
Kura Oncology
KURA
+$4.22M
5
THRD
Third Harmonic Bio
THRD
+$2.94M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.15B
$95.4M 10.9%
3,670,206
– –
TNGX icon
2
Tango Therapeutics
TNGX
$4.48B
$55M 6.28%
10,736,000
– –
COGT icon
3
Cogent Biosciences
COGT
$6.45B
$50M 5.71%
6,964,375
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$1.95B
$49.4M 5.64%
5,319,148
– –
CDTX
5
DELISTED
Cidara Therapeutics
CDTX
$49M 5.6%
1,005,901
– –
ABVX
6
Abivax
ABVX
$11.8B
$46.3M 5.29%
6,056,596
– –
AMLX icon
7
Amylyx Pharmaceuticals
AMLX
$1.89B
$38.1M 4.35%
5,943,812
– –
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$38M 4.34%
2,890,816
– –
FULC icon
9
Fulcrum Therapeutics
FULC
$236M
$36.1M 4.13%
5,250,000
– –
DYN icon
10
Dyne Therapeutics
DYN
$3.74B
$35.9M 4.1%
3,766,660
+1,116,510
+42% +$12.3M
EYPT icon
11
EyePoint Inc
EYPT
$1.08B
$33.6M 3.84%
3,572,335
– –
UPB
12
Upstream Bio Inc
UPB
$385M
$30.8M 3.51%
2,801,763
– –
SVRA icon
13
Savara
SVRA
$1.14B
$28.2M 3.22%
12,362,205
– –
DNTH icon
14
Dianthus Therapeutics
DNTH
$5.15B
$28M 3.2%
1,501,624
– –
TYRA icon
15
Tyra Biosciences
TYRA
$1.87B
$27.7M 3.17%
2,898,103
– –
IRON icon
16
Disc Medicine
IRON
$2.83B
$24.6M 2.81%
465,257
– –
TRML
17
DELISTED
Tourmaline Bio
TRML
$23.6M 2.7%
1,477,593
– –
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.3B
$23.2M 2.65%
+697,003
New +$21.1M
GPCR icon
19
Structure Therapeutics
GPCR
$3.3B
$22M 2.52%
1,063,000
– –
XNCR icon
20
Xencor
XNCR
$1.09B
$19.3M 2.2%
2,452,138
– –
SLN
21
Silence Therapeutics
SLN
$492M
$17.6M 2.01%
3,033,560
– –
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$15.6M 1.78%
186,250
-88,750
-32% -$6.64M
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$14.8M 1.69%
2,761,861
– –
RAPT
24
DELISTED
RAPT Therapeutics
RAPT
$13.1M 1.5%
1,636,275
– –
THRD
25
DELISTED
Third Harmonic Bio
THRD
$10.4M 1.19%
1,915,424
-590,000
-24% -$2.94M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.51B AUM 39.24% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $3.51B AUM 13.98% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return